Suppliers and packagers for generic pharmaceutical drug: bexagliflozin

bexagliflozin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373	NDA AUTHORIZED GENERIC	Golden State Medical Supply, Inc.	51407-918-30	30 TABLET in 1 BOTTLE (51407-918-30)	2023-01-20
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373	NDA AUTHORIZED GENERIC	Golden State Medical Supply, Inc.	51407-918-90	90 TABLET in 1 BOTTLE (51407-918-90)	2023-01-20
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373	NDA AUTHORIZED GENERIC	TheracosBio, LLC	82381-2000-8	30 TABLET in 1 BOTTLE (82381-2000-8)	2024-03-19
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373	NDA AUTHORIZED GENERIC	TheracosBio, LLC	82381-2000-9	90 TABLET in 1 BOTTLE (82381-2000-9)	2024-03-19
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373	NDA	TheracosBio, LLC	82381-2174-1	30 TABLET in 1 BOTTLE (82381-2174-1)	2023-07-13

Bexagliflozin Supply Chain Analysis

Last updated: February 19, 2026

Key Suppliers and Manufacturing Landscape

Bexagliflozin, a novel oral once-daily selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, is developed for the treatment of type 2 diabetes mellitus. Its commercialization necessitates a robust and compliant supply chain, encompassing active pharmaceutical ingredient (API) manufacturing and drug product formulation. The market for SGLT2 inhibitors is competitive, with established players and ongoing research driving demand for efficient and cost-effective manufacturing. This analysis identifies key suppliers and examines the manufacturing landscape relevant to bexagliflozin.

API Manufacturing

The synthesis of bexagliflozin API involves complex multi-step chemical processes. Pharmaceutical companies typically outsource API manufacturing to specialized contract development and manufacturing organizations (CDMOs) or rely on in-house facilities. The selection of an API supplier is contingent on factors including Good Manufacturing Practice (GMP) compliance, capacity, cost, and intellectual property considerations.

• Potential API Manufacturers: While specific bexagliflozin API manufacturers are not publicly disclosed by developers like Sigmapharm Laboratories, LLC, the general landscape of API suppliers for complex small molecules includes companies with expertise in heterocyclic chemistry, chiral synthesis, and large-scale GMP production. These include:

  • Lonza: A global CDMO with extensive capabilities in small molecule API development and manufacturing.
  • Catalent: Offers integrated services from development to commercial manufacturing of APIs.
  • Samsung Biologics: While more known for biologics, they also have small molecule API capabilities.
  • WuXi AppTec: A leading global pharmaceutical and medical device open-access capability and technology platform company, offering API development and manufacturing services.

• Key Considerations for API Sourcing:

  • Regulatory Compliance: Suppliers must adhere to strict GMP guidelines as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Audits and quality agreements are critical.
  • Process Chemistry and Scale-Up: The ability to efficiently and reproducibly scale up the synthesis from laboratory to commercial quantities is paramount. Robust process development minimizes impurities and ensures yield.
  • Cost of Goods Sold (COGS): API costs are a significant component of overall drug manufacturing expenses. Competitive pricing without compromising quality is essential.
  • Supply Chain Security and Redundancy: Diversifying suppliers or establishing robust contingency plans can mitigate risks associated with single-source dependencies, geopolitical instability, or unforeseen events.

Drug Product Formulation and Manufacturing

Once the API is synthesized, it is formulated into the final dosage form, typically an oral tablet for bexagliflozin. This process involves blending the API with excipients such as binders, fillers, disintegrants, and lubricants, followed by granulation, compression, and potentially coating.

• CDMOs for Drug Product Manufacturing: Similar to API sourcing, pharmaceutical companies often partner with CDMOs for the formulation and commercial manufacturing of the finished drug product.

  • Patheon (part of Thermo Fisher Scientific): A major global CDMO providing comprehensive drug product manufacturing services.
  • Aptar Pharma: While primarily known for drug delivery devices, they also offer formulation development and some manufacturing services.
  • Cerbios-Pharma SA: Offers services for sterile and non-sterile drug products, including oral solid dosage forms.
  • SK Biotek (now SK pharmteco): Provides integrated services from API to finished dosage forms.

• Excipient Suppliers: The quality and reliability of excipient suppliers are crucial for product performance and stability. Major excipient manufacturers include:

  • Ashland: Offers a wide range of pharmaceutical excipients, including binders, disintegrants, and coatings.
  • DuPont Nutrition & Biosciences (now IFF): Provides a portfolio of cellulosic derivatives and other functional excipients.
  • Roquette: A global leader in plant-based ingredients, supplying starches and polyols for pharmaceutical formulations.
  • Colorcon: Specializes in coating systems and excipients for solid oral dosage forms.

• Key Considerations for Drug Product Sourcing:

  • Dosage Form Uniformity and Bioavailability: The formulation must ensure consistent API content per tablet and predictable drug release for optimal therapeutic effect.
  • Stability and Shelf-Life: The chosen excipients and manufacturing processes must guarantee the product's stability throughout its intended shelf-life under various storage conditions.
  • Packaging: Primary and secondary packaging must protect the drug product from environmental factors and ensure tamper-evidence and patient compliance. Suppliers specializing in blister packaging, bottles, and carton printing are relevant.
  • Regulatory Filings and Inspections: Manufacturing sites must be approved by regulatory authorities, and any changes in formulation or manufacturing sites require regulatory notification or approval.

Intellectual Property and Regulatory Landscape

The intellectual property surrounding bexagliflozin and its manufacturing processes is a critical factor in supply chain strategy. Patents covering the compound, its polymorphic forms, synthetic routes, and formulations can influence sourcing decisions and market exclusivity.

• Patent Exclusivity: The patent landscape for bexagliflozin, as with other novel drugs, dictates the period of market exclusivity. The expiration of key patents can open opportunities for generic manufacturers, leading to shifts in the supply chain and increased competition. Information regarding bexagliflozin's patent status can be found in databases like the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO).

  • For instance, initial patent applications related to SGLT2 inhibitors, including bexagliflozin, were filed in the late 2000s and early 2010s, with subsequent patents covering specific aspects of the molecule and its synthesis. [1]
  • The U.S. Food and Drug Administration's (FDA) Orange Book lists approved drugs and their patent information, which is a key resource for understanding patent exclusivity.

• Regulatory Filings: The submission of a New Drug Application (NDA) or equivalent to regulatory agencies requires detailed information about the API and drug product manufacturing processes, including sites, quality control measures, and stability data.

  • The manufacturing processes described in the NDA must be validated and compliant with current Good Manufacturing Practices (cGMP).
  • Any post-approval changes to manufacturing processes, suppliers, or sites typically require regulatory review and approval, impacting supply chain flexibility.

Commercialization and Market Trends

The commercial success of bexagliflozin will be influenced by its clinical profile, pricing, and the competitive landscape of the SGLT2 inhibitor market. The market for SGLT2 inhibitors has seen significant growth, driven by their efficacy in glycemic control and emerging evidence of cardiovascular and renal benefits.

• Competitive Landscape: Key competitors in the SGLT2 inhibitor class include:

  • Empagliflozin (Jardiance): Developed by Boehringer Ingelheim and Eli Lilly.
  • Dapagliflozin (Farxiga/Forxiga): Developed by AstraZeneca.
  • Canagliflozin (Invokana): Developed by Janssen Pharmaceuticals.
  • Ertugliflozin (Steglatro): Developed by Merck & Co. and Pfizer.

• Supply Chain Resilience: The COVID-19 pandemic highlighted the importance of resilient supply chains. Pharmaceutical companies are increasingly focusing on:

  • Geographic Diversification: Reducing reliance on single countries or regions for API or finished product manufacturing.
  • Inventory Management: Strategically managing inventory levels to buffer against disruptions.
  • Digitalization: Implementing digital tools for enhanced supply chain visibility and control.

• Cost Optimization: As patent cliffs approach for some older SGLT2 inhibitors, there is increased pressure to optimize manufacturing costs for newer entrants like bexagliflozin to ensure market competitiveness. This can involve continuous process improvement and strategic sourcing.

Supplier Assessment Framework

A comprehensive framework for assessing potential bexagliflozin suppliers should include:

1. Quality and Compliance:

   • GMP certification and inspection history (FDA, EMA, etc.).
   • Quality management system (QMS) robustenss.
   • Analytical capabilities and method validation.
   • Impurity profiling and control strategies.
   • Change control processes.

2. Technical Capabilities:

   • Expertise in relevant chemical synthesis or formulation technologies.
   • Process development and scale-up experience.
   • Capacity and lead times.
   • Technology transfer capabilities.

3. Financial Stability and Business Practices:

   • Financial health and long-term viability.
   • Ethical business practices and reputation.
   • Intellectual property protection policies.

4. Supply Chain Management:

   • Risk management strategies (e.g., single-source risk, raw material sourcing).
   • Business continuity and disaster recovery plans.
   • Logistics and cold chain capabilities (if applicable).

Key Takeaways

Bexagliflozin's successful market entry and sustained commercial performance are critically dependent on a secure, compliant, and cost-effective supply chain. The identification and qualification of reliable API manufacturers and drug product CDMOs are paramount. These partners must demonstrate rigorous adherence to GMP, possess advanced technical capabilities for complex synthesis and formulation, and exhibit robust quality and supply chain management systems. The evolving regulatory environment and the competitive SGLT2 inhibitor market necessitate a proactive approach to supply chain resilience, cost optimization, and continuous process improvement to secure market share and ensure patient access.

Frequently Asked Questions

What are the primary regulatory bodies overseeing bexagliflozin manufacturing?

The primary regulatory bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with other national health authorities in markets where bexagliflozin will be commercialized.

How does intellectual property impact the selection of bexagliflozin suppliers?

Intellectual property, particularly patents covering synthesis routes or specific polymorphic forms, can restrict the sourcing options for API manufacturers and influence the manufacturing processes that can be legally employed.

What are the typical lead times for API and drug product manufacturing?

Lead times can vary significantly based on the complexity of the synthesis or formulation, the scale of production, and the supplier's current capacity. Typical lead times for API development and commercial production can range from 6 to 18 months, while drug product manufacturing can range from 3 to 9 months.

What is the significance of a supplier's quality management system (QMS)?

A robust QMS is essential for ensuring consistent product quality, regulatory compliance, and risk mitigation. It encompasses all aspects of manufacturing, from raw material control to finished product release, and is a primary focus during supplier audits.

How do SGLT2 inhibitor market trends influence bexagliflozin's supply chain strategy?

Market trends, such as the introduction of generic competitors for established SGLT2 inhibitors, pricing pressures, and evolving clinical guidelines regarding cardiovascular and renal benefits, necessitate a supply chain strategy focused on cost-efficiency, scalability, and flexibility to adapt to market demands and competitive pressures.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patents & Patent Applications. Retrieved from https://www.uspto.gov/patents